Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is now available in the United States for the treatment of vernal keratoconjunctivitis (VKC), a rare and recurrent allergic eye condition that causes severe inflammation of the surface of the eye. Verkazia – which is administered as an eye drop – is